Mitochondrial replacement therapies (MRTs) represent a significant leap in reproductive medicine. Specifically, these techniques aim to prevent the transmission of life-threatening mitochondrial DNA (mtDNA) mutations from mother to child. By replacing defective maternal mitochondria with healthy donor organelles, clinicians can potentially eliminate heritable diseases. Therefore, this article explores the current clinical landscape, focusing on recent breakthroughs and the persistent challenges of these interventions.

Techniques in Mitochondrial Replacement Therapies

Currently, clinicians primarily utilize two methods: maternal spindle transfer (MST) and pronuclear transfer (PNT). MST involves moving the nuclear genetic material from an unfertilized oocyte into a donor egg. Conversely, PNT transfers the pronuclei after fertilization has occurred between zygotes. Both methods ensure that the offspring inherits the nuclear genome of the parents while receiving healthy mitochondria from a third-party donor. However, researchers are still debating which approach yields the most reliable results in long-term clinical settings.

Clinical Progress and the Reversion Challenge

Recently, the United Kingdom and Australia have emerged as leaders in MRT application. For instance, reports indicate that several healthy babies have been born using these strategies in controlled clinical trials. Furthermore, studies suggest high fertilization and pregnancy rates in specific patient cohorts, such as those with diminished ovarian reserve. Despite this success, technical pitfalls remain. For example, the phenomenon of "reversion" occurs when small amounts of carried-over maternal mtDNA expand during development. Consequently, this can lead to the recurrence of the very diseases the therapy intended to prevent. As a result, monitoring these outcomes is essential for developing future safety protocols.

Regulatory Status and Future Outlook

In India, mitochondrial replacement therapies are currently not permitted under the existing regulatory framework. While global interest grows, ethical and safety concerns necessitate cautious implementation. Moving forward, large-scale clinical trials and improved sequencing technologies will be vital for progress. Ultimately, these advancements will help mitigate risks associated with heteroplasmy and ensure the long-term health of children born through these pioneering techniques.

Frequently Asked Questions

What is the primary goal of mitochondrial replacement therapies?

The primary goal is to prevent the inheritance of pathogenic mitochondrial DNA mutations. This allows mothers with mitochondrial diseases to have genetically related children without passing on the disorder.

How does maternal spindle transfer differ from pronuclear transfer?

Maternal spindle transfer occurs before fertilization by moving the mother's nuclear material into a donor egg. In contrast, pronuclear transfer happens after fertilization by moving the pronuclei between zygotes.

Is MRT available for clinical use in India?

No, the procedure is currently not permitted in India. Regulatory frameworks are still evolving to address the ethical and technical complexities of these germline-related interventions.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional recommendation. It is not intended to replace consultation with a qualified healthcare provider. Refer to the latest local and national guidelines for clinical practice.

References

Costa-Borges N et al. Revisiting the promise and pitfalls of mitochondrial replacement therapies. Hum Reprod. 2026 Mar 08. doi: undefined. PMID: 41795216.

Hyslop LA et al. Pronuclear-transfer procedure and comparison of embryo development. New England Journal of Medicine. 2025 Jul; 393(3): 120-135.

MitoCanada. 2024 Healthcare Trends in Mitochondrial Disease. Published March 2024. Accessed March 2026.